Fast-Acting Botulinum Toxin Type E for Rapid Cosmetic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cosmetic and surgical treatments face challenges in effectively reducing muscle activity and scarring, particularly in procedures like glabellar lines and post-surgical scars, where existing neurotoxins have slow onset and long duration of action, and may cause significant side effects.
Innovation Solution
The use of a 'fast-acting' and 'fast-recovery' botulinum toxin type E, which can be administered alone or in combination with slower-acting neurotoxins, to reduce muscle activity and scarring by injecting it into specific muscle sites before or after surgical procedures, promoting elastin and collagen production and minimizing scarring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If traditional neurotoxins are used for cosmetic treatments, then muscle activity is reduced, but the onset is slow and duration is long
Solution Approach 1:
The patent segments the neurotoxin market by introducing a new type (Type E) with distinct kinetic properties separate from traditional types (A, B, C, D, F, G). This segmentation allows patients to choose based on desired duration, resolving the contradiction between fast onset and long duration by offering different segments for different needs.
Solution Approach 2:
The patent changes the biochemical parameters of the neurotoxin by using Type E botulinum toxin, which has inherently different enzymatic activity and binding characteristics compared to traditional types. This parameter change results in faster onset (2-4 hours vs. days) and shorter duration (14-30 days vs. months), directly resolving the technical contradiction.
2Reliability
If traditional neurotoxins are used for cosmetic treatments, then muscle activity is reduced, but side effects are significant
Solution Approach 1:
The patent changes the dosage parameters by using Type E toxin which achieves equivalent muscle relaxation at lower units due to faster onset and shorter duration. This parameter change reduces the risk of overtreatment and associated side effects like ptosis, brow droop, and asymmetry, while maintaining treatment reliability.
Solution Approach 2:
The patent implements periodic treatment with shorter intervals (every 14-30 days) compared to traditional neurotoxins (every 3-6 months). This periodic action allows for better control and reversal of effects if side effects occur, improving reliability while reducing harmful factors through more frequent but shorter-duration treatments.
3Object-affected harmful factors
If botulinum toxin is administered before surgical procedures, then muscle tension is reduced, but scarring prevention is not guaranteed
Solution Approach 1:
The patent applies preliminary action by administering Type E botulinum toxin 1-2 weeks before surgical procedures to reduce muscle tension at the incision site. The fast onset ensures muscle relaxation is established before surgery, and the shorter duration means normal muscle function returns after healing, preventing scarring while maintaining appropriate duration.
Solution Approach 2:
The patent changes the timing parameters by using the fast onset of Type E toxin to achieve muscle relaxation within days rather than weeks, allowing for optimized scheduling around surgical procedures. The shorter duration parameter ensures muscle function returns after scar healing, providing scarring prevention without prolonged muscle weakness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fast-acting botulinum toxin type E provides rapid cosmetic effects within 24 hours, lasting between 14 to 30 days, with fewer side effects and reduced scarring, offering a more predictable and shorter duration of treatment results compared to traditional neurotoxins.
Implementation Method 1
botulinum neurotoxins inhibit the release of acetylcholine at the neuromuscular junction, thereby reducing muscle activity
Data Source
AI summary
Disclosed herein are compositions and methods for use in therapeutic procedures. Use of a “fast-acting” botulinum toxin for cosmetic treatment and/or to prevent or reduce scarring. “Fast-acting” refers to a botulinum toxin that produces effects in the patient more rapidly than those produced by, for example, a botulinum neurotoxin type A. The “fast-acting” botulinum toxin, for example, type E.